The Trifecta valve has been reported to have valve dysfunction months to years after operation. However there were no reports of intraoperative valve dysfunction. A 73-year-old man with aortic stenosis underwent aortic valve replacement using a 21-mm Trifecta valve with Glide Technology (Trifecta GT; Abbot). Hemodynamics were collapsed after aortic declamp because of severe regurgitation, and we replaced it with another biologic valve. We noticed that the removed valve's mount post was open outwardly more than usual. Despite the progress of the biologic valve, dysfunction like this case can occur during operation, and it is important to reoperate immediately even if there is no obvious tear or deformity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.athoracsur.2020.12.039 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Perceval sutureless bioprosthesis versus Trifecta sutured bioprosthesis for aortic valve replacement: immediate results of the study.
Kardiochir Torakochirurgia Pol
September 2024
Division of Cardiac Surgery, Department of Surgical Sciences, Tor Vergata University of Rome, Rome, Italy.
Introduction: The Perceval sutureless biological prosthesis for aortic valve replacement has been introduced with the rationale for shortening surgical, extracorporeal circulation and aortic cross-clamping times, in order to reduce postoperative complications.
Aim: To evaluate early hemodynamic performance and immediate outcomes of implantation of the Perceval sutureless bioprosthesis in comparison with the St. Jude Trifecta sutured bioprosthesis for aortic valve replacement (Perfecta study).
Real-world outcomes and management considerations following surgical aortic valve replacement with the Trifecta valve.
Cardiovasc Revasc Med
October 2024
Division of Cardiovascular Surgery, Thomas Jefferson University Hospitals, Philadelphia, PA, United States of America.
Background: Bioprosthetic surgical aortic valve replacement (SAVR) using the Trifecta valve was frequently chosen because of its large opening area and low transvalvular gradient. However, long-term follow-up revealed the potential for early structural valve deterioration. To further assess the long-term clinical outcomes and management considerations for patients implanted with the Trifecta valve, a real-world study using Medicare fee-for-service claims data was conducted with a focus on Trifecta valve reintervention.
View Article and Find Full Text PDFEfficacy of a sutureless aortic valve-reoperative alternative to a composite graft replacement.
Multimed Man Cardiothorac Surg
October 2024
Department of Cardiovascular Surgery, Chiba-Nishi General Hospital, Chiba, Japan.
Findings in the present case underscore the potential of sutureless aortic valve utilization in patients with prior prosthetic root replacement, thereby obviating the need for high-risk procedures such as replacing a prosthetic root or reimplanting a coronary artery. A 75-year-old male who had undergone a Bio-Bentall operation with a bioprosthetic Trifecta valve for aortic regurgitation and annuloaortic ectasia eight years prior presented with symptoms of heart failure, notably dyspnoea, attributed to prosthetic valve dysfunction. Although a transcatheter aortic valve implant is often recommended, it was deemed unsuitable in this case due to a history of type B aortic dissection.
View Article and Find Full Text PDFTotally Endoscopic Valve-in-Valve Procedure: Implantation of Perceval Prosthesis in Trifecta Ring.
Innovations (Phila)
October 2024
Department of Cardiothoracic Surgery, Jessa Hospital, Hasselt, Belgium.
Comparison of four aortic bioprostheses: Hancock II St Jude Trifecta Carpentier-Edwards Perimount Magna Magna Ease-mid-term results (COMPARE SAVR study).
J Thorac Dis
August 2024
CAROL-Cardiothoracic Anatomy Research Operative Lab, Department of Cardiovascular Surgery and Transplantology, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland.
Background: In the era of percutaneous aortic valve implantation, biological valves are the preferred prostheses implanted in patients undergoing surgical aortic valve replacement (sAVR). The aim was to present a real-life analysis of mid-term sAVR outcomes for the four aortic bioprostheses: the Hancock II, the Carpentier-Edwards Perimount Magna, the Carpentier-Edwards Perimount Magna Ease and the Trifecta valve.
Methods: This is a retrospective study based on data from the Polish National Cardiac Surgery Database.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!